ArticleHCA healthcare journal of medicine2025
Severity of SARS-CoV-2 Illness in Patients With Type 1 and Type 2 Diabetes Mellitus.
Article in HCA healthcare journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes is a well-known risk factor for the severity of illness in patients with SARS-CoV-2 infection (COVID-19). However, there is less published data on illness severity differences between patients with type 1 (T1D) and type 2 (T2D) diabetes mellitus. Methods: We performed a retrospective review of records of patients with COVID-19 (March 2020 - November 2020) extracted from a large, private hospital system database. Of the 76 467 patients with COVID-19, 54 007 (70.6%) did not have a diabetes diagnosis (NON), 22 084 (28.9%) had T2D, and 376 (0.49%) had T1D. We further subgrouped diabetic patients into groups with A1C above 7% (T2D7 and T1D7) or above 8% (T2D8 and T1D8). Logistic regression analysis was used to determine the association between selected predictor variables and our primary outcome variables of ventilator, intensive care unit (ICU) admission, mortality, and length of stay. Results: Patients with T2D were substantially older (62.9 years) than NON (48.8) or T1D (43.2). The proportion of Black, White, and other race patients was similar, with a somewhat higher proportion of Black patients having T1D. Patients with T1D and T2D had significantly higher odds of requiring a ventilator, being admitted to ICU, and had a higher mortality rate than NON. As an example, T1D had 5.68 higher odds and T2D 1.82 higher odds of ICU admission compared to NON. T2D patients with A1C above 7% or 8% were roughly 2 times more likely to require a ventilator, were less likely to be admitted to the ICU, and had a roughly 3-day longer length of stay than T1D patients with A1C above 7% or 8%. Conclusion: Both T1D and T2D were independent predictors of illness severity for SARS-CoV-2 patients, leading to higher odds of requiring ventilation, ICU admission, mortality, and hospital stay duration. Our older patient group with T2D had somewhat worse outcomes and longer hospital stays than T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.